Uncategorized

CAMBRIDGE, Mass. , Jan. 24, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with two newly hired employees that, among other things, provide for

– Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and

CAMBRIDGE, Mass. , Jan. 04, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that CEO Alfred W. Sandrock , Jr., M.D., Ph.D., will present at the upcoming 41st Annual J.P.

CAMBRIDGE, Mass. , Dec. 14, 2022 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Grace E. Colón, Ph.D., to its Board of Directors. Dr.

CAMBRIDGE, Mass. , Nov. 29, 2022 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into an employment agreement with a newly hired employee that, among other things, provides for

– Voyager’s TRACER TM capsid platform validated by Pfizer option exercise – – Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER – – Pipeline programs advancing; development candidate selections for lead programs expected Q4 2022 to H1 2023 – –

CAMBRIDGE, Mass. , Nov. 01, 2022 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced it will report third quarter 2022 financial and

CAMBRIDGE, Mass. , Oct. 18, 2022 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, has entered into an employment agreement with a newly hired employee

– Data presented at European Society of Gene & Cell Therapy (ESGCT) Congress 2022 – – Receptor findings support potential for human translation of Voyager’s capsids and may help overcome barriers to CNS drug delivery – CAMBRIDGE, Mass. , Oct. 11, 2022 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc.

– Data presented at European Society of Gene & Cell Therapy (ESGCT) Congress 2022 – – Receptor findings support potential for human translation of Voyager’s capsids and may help overcome barriers to CNS drug delivery – CAMBRIDGE, Mass. , Oct. 11, 2022 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc.